help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, J. L.
Right arrow Articles by Baxter, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, J. L.
Right arrow Articles by Baxter, R. C.

Endocrinology, Vol 127, 781-788, Copyright © 1990 by Endocrine Society


ARTICLES

Production of an insulin-like growth factor (IGF)-inducible IGF-binding protein by human skin fibroblasts

JL Martin and RC Baxter
Department of Medicine, University of Sydney, New South Wales, Australia.

Neonatal human skin fibroblasts produce insulin-like growth factor- binding proteins (IGFBPs) that have the potential to modulate the actions of the growth factors. We have examined the IGFBPs secreted by monolayer cultures of neonatal fibroblasts by ligand blotting with [125I]IGF-II and immunoblotting with antisera raised against three well characterized IGFBPs: IGFBP-1, IGFBP-2, and IGFBP-3. As detected by ligand blotting, medium from untreated fibroblasts contained IGFBP-3, a second IGFBP which appeared as a doublet of 29-31 K, and a smaller protein of 22 K. Within 10 h of the addition of 50 ng/ml IGF-I, a markedly increased level of production of the 29-31 K IGFBP doublet was detectable, with levels increasing 8- to 9-fold by 24 h compared to that in untreated samples. IGF-I was approximately twice as potent as IGF-II at inducing 29-31 K IGFBP, with a half-maximal response at 15.4 +/- 2.7 ng/ml IGF-I and 26.6 +/- 1.6 ng/ml IGF-II (n = 3). Insulin tested at 1 microgram/ml did not induce 29-31 K IGFBP. Neither GH nor the acid-labile subunit of the circulating high mol wt IGFBP complex induced 29-31 K IGFBP or affected its induction by IGF-I or IGF-II. Immunoblotting demonstrated that IGF-inducible IGFBP did not react with antibodies to IGFBP-1, IGFBP-2, or IGFBP-3. These results indicate that IGF-I and IGF-II induce an IGFBP that is different from previously characterized human IGFBPs.


This article has been cited by other articles:


Home page
Endocr. Rev.Home page
S. R. Edmondson, S. P. Thumiger, G. A. Werther, and C. J. Wraight
Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems
Endocr. Rev., December 1, 2003; 24(6): 737 - 764.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Fanayan, S. M. Firth, and R. C. Baxter
Signaling through the Smad Pathway by Insulin-like Growth Factor-binding Protein-3 in Breast Cancer Cells. RELATIONSHIP TO TRANSFORMING GROWTH FACTOR-beta 1 SIGNALING
J. Biol. Chem., February 22, 2002; 277(9): 7255 - 7261.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Fanayan, S. M. Firth, A. J. Butt, and R. C. Baxter
Growth Inhibition by Insulin-like Growth Factor-binding Protein-3 in T47D Breast Cancer Cells Requires Transforming Growth Factor-beta (TGF-beta ) and the Type II TGF-beta Receptor
J. Biol. Chem., December 8, 2000; 275(50): 39146 - 39151.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society